Clinical pharmacology

Creatinine Clearance (CrCl): The Cockcroft-Gault Formula Explained

Creatinine clearance (CrCl) estimated by the Cockcroft-Gault equation is the pharmacokinetic standard for drug dosing in kidney disease. Learn how the formula works, why it differs from eGFR, how to choose the right body weight, and what CrCl thresholds matter for common medications.

March 31, 2026 · 7 min readLast updated: March 31, 2026

HealthClinical

Free online tool

Creatinine clearance

Try the calculator →

What Is Creatinine Clearance?

Creatinine clearance (CrCl) is the volume of blood that the kidneys clear of creatinine per minute, expressed in mL/min. It is a direct proxy for the glomerular filtration rate (GFR) — the fundamental measure of kidney filtering capacity. Unlike the estimated GFR (eGFR) used for chronic kidney disease (CKD) staging, CrCl is not normalized to body surface area, making it an absolute value that reflects the actual drug-clearance capacity of an individual patient's kidneys.

The Cockcroft-Gault Equation

Published in 1976 by Donald Cockcroft and Henry Gault in the journal Nephron, this formula remains the pharmacokinetic gold standard for renal drug dosing after nearly 50 years. The equation is: CrCl (mL/min) = ((140 − age) × weight [kg] × [0.85 if female]) ÷ (72 × serum creatinine [mg/dL]).

Formula Components

140 − age

Age adjustment

Reflects the physiological decline in muscle mass and creatinine production with age. CrCl decreases approximately 1 mL/min per year after age 40.

× weight (kg)

Muscle mass proxy

Creatinine is a byproduct of muscle metabolism, so body weight serves as a proxy for muscle mass and creatinine production rate. Use actual body weight for most patients.

× 0.85 (female)

Sex correction

Women have approximately 15% less muscle mass than men at the same weight, producing less creatinine. The 0.85 factor corrects for this systematic difference.

÷ 72 × SCr

Normalization

Divides by the product of 72 (an empirical constant from the original study) and serum creatinine in mg/dL. Higher creatinine = lower estimated clearance.

CrCl vs. eGFR: Key Differences

Patients and clinicians often confuse CrCl with eGFR. Both estimate kidney function from serum creatinine, but they serve different purposes. eGFR (using CKD-EPI 2021) is normalized to 1.73 m² body surface area and is the standard for CKD diagnosis and staging per KDIGO 2024 guidelines. CrCl (Cockcroft-Gault) is absolute, not normalized, and is the metric referenced in virtually all drug prescribing information and clinical pharmacokinetic studies. For an average-sized adult, the two values are similar; they diverge significantly in very obese or very underweight patients. When adjusting drug doses, always use CrCl — the FDA and EMA require Cockcroft-Gault in renal impairment drug labeling.

Choosing the Right Body Weight

Body weight selection is the most common clinical challenge with the Cockcroft-Gault formula. The original study used actual body weight (ABW). Guidelines differ on obese patients:

Body Weight Guidelines

ABW (Actual)

BMI ≤ 30

Use actual body weight for patients at or below their ideal body weight. This is the most common scenario and the formula's intended use.

AdjBW (Adjusted)

BMI > 30

Adjusted body weight = Ideal body weight + 0.4 × (ABW − IBW). Used for obese patients to prevent overestimating CrCl. Ask a clinical pharmacist when in doubt.

IBW (Ideal)

Cachexia/frailty

Some guidelines use ideal body weight for cachectic or markedly underweight patients to prevent underestimating CrCl. Requires clinical judgment.

Drug Dosing Thresholds

The primary clinical use of CrCl is identifying when drug doses need adjustment. Thresholds vary by drug, but the most common are:

Common CrCl Dose-Adjustment Thresholds

CrCl ≥ 50 mL/min

Usually full dose

Most drugs can be used at standard doses. Always verify product labeling, especially for narrow therapeutic index drugs.

CrCl 30–49 mL/min

Dose reduction often

Metformin (monitor closely), many antibiotics (penicillins, cephalosporins, fluoroquinolones), gabapentin, pregabalin, digoxin. Check individual drug labeling.

CrCl 15–29 mL/min

Significant adjustment

Metformin contraindicated in many guidelines; NSAIDs should be avoided; direct oral anticoagulants (DOACs) require significant dose reduction or avoidance; many antibiotics need dose reduction.

CrCl < 15 mL/min

Specialist required

Dialysis-level renal failure. Most renally-cleared drugs require specialist oversight. Many are contraindicated. Dialysis clearance must be factored in.

Normal Values and Age-Related Decline

CrCl is highest in young adults and declines with age due to nephron loss and reduced muscle mass. Population-based normal ranges: men aged 20–30: 100–130 mL/min; women aged 20–30: 85–115 mL/min. After age 40, CrCl decreases approximately 1 mL/min per year in both sexes. By age 80, many healthy individuals have CrCl values of 50–70 mL/min — classified as mildly to moderately reduced by standard thresholds, even without kidney disease. This physiological reality is important when interpreting results in elderly patients.

Limitations of the Cockcroft-Gault Equation

Despite its widespread use, the Cockcroft-Gault formula has known limitations. It was derived from 249 patients (mostly male, hospitalized, with stable renal function) in the 1970s — a non-representative sample by modern standards. The formula can overestimate CrCl in obese patients (overestimates muscle mass), underestimate in cachectic patients, be inaccurate in unstable renal function (acute kidney injury), and be unreliable in patients with extreme muscle mass (bodybuilders, amputees). For CKD staging and diagnosis, eGFR (CKD-EPI 2021) is more accurate. For drug dosing, Cockcroft-Gault remains the regulatory standard because it is the formula used in nearly all drug pharmacokinetic studies.

Sources